 |
Top 7 Multiple Sclerosis startups in USA
Sep 28, 2025 | By Jason Kwon | 20 |
1
Funding: $535.8M
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, multiple sclerosis (MS).
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, multiple sclerosis (MS).
2
Funding: $183M
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class that advances programs in multiple sclerosis and psoriasis
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class that advances programs in multiple sclerosis and psoriasis
3
Funding: $142.1M
Octave is a biotechnology company that uses precision medicine and scientific insights to treat patients with multiple sclerosis.
Octave is a biotechnology company that uses precision medicine and scientific insights to treat patients with multiple sclerosis.
4
Funding: $135.5M
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
5
Funding: $70M
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
6
Funding: $15.7M
28bio's Nerve-on-a-Chip platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
28bio's Nerve-on-a-Chip platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
7
BeCare Link connects patients to physicians and researchers, through the use of a user-friendly mobile app, to provide unprecedented levels of insight about MS and other neurodegenerative diseases.
★
See also:
